1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Field Trip Health Ltd.
  6. News
  7. Summary
    FTRP   CA31656R1029

FIELD TRIP HEALTH LTD.

(FTRP)
  Report
Delayed Toronto Stock Exchange  -  03:59 2022-08-05 pm EDT
1.070 CAD    0.00%
08/05Field Trip Health Ltd. Gets Conditional Approval for Listing of Common Shares of Field Trip Health & Wellness Ltd. on the TSX Venture Exchange
MT
08/04Field Trip Health Ltd. Receives Conditional Approval for Listing of Common Shares of Field Trip Health & Wellness Ltd. on the TSX Venture Exchange
AQ
07/29FIELD TRIP HEALTH : ANNOUNCES FIRST DOSINGS IN PHASE I CLINICAL STUDY OF FT-104 - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Swoon Late, Closing Lower

06/30/2022 | 04:07pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ANGION BIOMEDICA CORP. 0.93% 1.09 Delayed Quote.-62.41%
BIONTECH SE 1.48% 183.11 Delayed Quote.-28.97%
CYTOKINETICS, INCORPORATED 10.92% 51.82 Delayed Quote.13.69%
FIELD TRIP HEALTH LTD. 0.00% 1.07 Delayed Quote.-65.03%
NASDAQ COMPOSITE -0.50% 12657.55 Real-time Quote.-19.10%
PFIZER, INC. -1.18% 49.27 Delayed Quote.-16.56%
UNIVERSAL HEALTH SERVICES, INC. 0.59% 110.35 Delayed Quote.-14.89%
All news about FIELD TRIP HEALTH LTD.
08/05Field Trip Health Ltd. Gets Conditional Approval for Listing of Common Shares of Field ..
MT
08/04Field Trip Health Ltd. Receives Conditional Approval for Listing of Common Shares of Fi..
AQ
07/29FIELD TRIP HEALTH : ANNOUNCES FIRST DOSINGS IN PHASE I CLINICAL STUDY OF FT-104 - Form 6-K
PU
07/21Field Trip Health Announces First Dosings in Phase I Clinical Study of FT-104
MT
07/21FIELD TRIP HEALTH BRIEF : Announces First Dosings in Phase I Clinical Study of FT-104
MT
07/21Field Trip Announces First Dosings in Phase I Clinical Study of FT-104
AQ
07/21Field Trip Health Ltd. Announces First Successful Dosings in the Phase 1 Clinical Study..
CI
07/05IIROC Trading Halt - FTRP.WT
AQ
06/30SECTOR UPDATE : Health Care Stocks Swoon Late, Closing Lower
MT
06/30SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on FIELD TRIP HEALTH LTD.
More recommendations
Financials
Sales 2023 7,83 M 6,04 M 6,04 M
Net income 2023 -42,1 M -32,5 M -32,5 M
Net Debt 2023 - - -
P/E ratio 2023 -1,64x
Yield 2023 -
Capitalization 62,2 M 48,1 M 48,1 M
Capi. / Sales 2023 7,95x
Capi. / Sales 2024 2,05x
Nbr of Employees 194
Free-Float 67,0%
Chart FIELD TRIP HEALTH LTD.
Duration : Period :
Field Trip Health Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FIELD TRIP HEALTH LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,07 CAD
Average target price 14,25 CAD
Spread / Average Target 1 232%
EPS Revisions
Managers and Directors
Joseph del Moral Chief Executive Officer & Director
Hannan Fleiman President & Director
Donna Wong Chief Financial Officer
Ronan Levy Executive Chairman
Ryan Yermus Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
FIELD TRIP HEALTH LTD.-65.03%48
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.80%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235